Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Opana ER Pulled from U.S. Market

Michele B. Kaufman, PharmD, BCGP  |  July 11, 2017

Endo Pharmaceuticals will work with the FDA to coordinate the organized removal of Opana ER from the U.S. market.

Filed under:AnalgesicsDrug Updates Tagged with:Drug SafetyOpana ERopioidOpioid abuse

Upadacitinib Meets Study Endpoints to Treat RA

Michele B. Kaufman, PharmD, BCGP  |  July 5, 2017

A recent clinical trial found that upadacitinib may effectively reduce disease activity at Week 12 for patients with moderate to severe rheumatoid arthritis…

Filed under:Drug Updates Tagged with:JAK inhibitorRheumatoid Arthritis (RA)upadacitinib

Changes in BMI Associated with Improvements in Disease Activity & Glucocorticoid Treatment

Arthritis Care & Research  |  July 4, 2017

A recent study examined the relationship between increased BMI and antineutrophil cytoplasmic antibody–associated vasculitis treatment with glucocorticoids. The results: Weight gain was independently associated with reductions in disease activity, increased glucocorticoid exposure and randomization to rituximab. The most significant increases in BMI occurred during the first six months of treatment, and newly diagnosed patients were more likely to experience an increase in BMI…

Filed under:ConditionsResearch RheumVasculitis Tagged with:ANCA-Associated VasculitisArthritis Care & ResearchBMIbody mass index (BMI)rituximabweight loss

Being Active May Reduce Risk of Chronic Low Back Pain

Shereen Lehman  |  June 30, 2017

(Reuters Health)—Regularly engaging in physical activity, from walking to intense exercise, may help to reduce the risk of chronic low back pain by, as much as 16%, according to a new review of previous studies. In the past, it hasn’t been clear whether physical activity staves off low back pain, or people without back pain…

Filed under:Soft Tissue Pain Tagged with:Back painExerciselow back painPainphysical activitywalking

Senate Republicans Unveil Obamacare Replacement Bill with Tough Debate Expected

Richard Cowan and Susan Cornwell  |  June 22, 2017

WASHINGTON (Reuters)—U.S. Senate Republicans on Thursday unveiled their version of legislation that would replace Obamacare, proposing to kill a tax on the wealthy that pays for it and reduce aid to the poor to cut costs. With Democrats deeply opposed to Republican attempts to overhaul former President Barack Obama’s signature healthcare law, the route to…

Filed under:Practice SupportProfessional Topics Tagged with:Obamacare replacement billSenate bill

FDA Requests Removal of Opana ER; Plus Abatacept’s New Dosing Option

Michele B. Kaufman, PharmD, BCGP  |  June 21, 2017

The FDA has asked the manufactures of Opana ER to remove the opioid from the U.S. market due to the public health risk of abuse…

Filed under:AnalgesicsBiologics/DMARDsDrug Updates Tagged with:abataceptFDAFood and Drug Administrationjuvenile idiopathic arthritis (JIA)Opana EROpioid abuseOpioidspolyarticular arthritispublic healthSafety

News Updates for Diclofenac Sodium, Denosumab & Sarilumab

Michele B. Kaufman, PharmD, BCGP  |  June 20, 2017

In drug news, a generic 2% diclofenac sodium solution is now available, denosumab is promising to treat osteoporosis, and the FDA has approved sarilumab to treat adults with RA…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabdiclofenac sodiumFDAFood and Drug Administrationgeneric drugsKnee Osteoarthritis (OA)OsteoporosisRheumatoid Arthritis (RA)sarilumab

FDA Responds to New Drug Application for Baricitinib

Michele B. Kaufman, PharmD, BCGP  |  June 15, 2017

Oxycodone Tablets Submitted to FDA Filings for oxycodone tablets (Oxaydo) in both 10 and 15 mg doses have been accepted by the U.S. Food and Drug Administration (FDA).1 The submission is based on a pharmacokinetic study demonstrating bioequivalence to the reference drug, oxycodone hydrochloride (Roxicodone) tablets at a 15 mg dose. The product is an…

Filed under:AnalgesicsConditionsDrug Updates Tagged with:analgesicApprovalsbaricitinibDisease-modifying antirheumatic drugs (DMARDs)drugFDAopioidOxycodonePsoriatic ArthritisQualityRARheumatoid arthritisSafetysecukinumabupdate

Clinical Guidelines for Sjögren’s Syndrome Focus on Biologics, Fatigue, Inflammatory Musculoskeletal Pain

Kurt Ullman  |  June 15, 2017

The first clinical practice guidelines for Sjögren’s syndrome have been released, the culmination of an initiative by the Sjögren’s Syndrome Foundation.1 These standard-of-care recommendations are intended to provide consistency in practice patterns, inform coverage and reimbursement policies, lead to the design and implementation of educational programs, highlight the needs for future research and fill a…

Filed under:ConditionsOther Rheumatic ConditionsSjögren’s Disease Tagged with:BiologicsClinicaldrug therapyfatigueguidelineinflammatory musculoskeletal diseasePainpatient carerecommendationRheumatic DiseaseSjogren'sTreatment

The Birth and Growth of Biotechnology, and the Impact of Biologic Drugs on Rheumatology

Simon M. Helfgott, MD  |  June 15, 2017

Here’s a trivia question: Where were the big ideas for the field of biotechnology first discussed? Answer: At a since-demolished delicatessen in Waikiki Beach, Hawaii. Go figure. The year was 1972, and Stanley Cohen, MD, professor of medicine at Stanford University in Palo Alto, Calif., and Herbert Boyer, PhD, a former professor and biochemist at the…

Filed under:Biologics/DMARDsOpinionResearch RheumRheuminationsSpeak Out Rheum Tagged with:BiologicsBiosimilarsbiotechnologyCongressDNAdrug costdrug therapypatient careResearchRheumatic DiseaserheumatologistrheumatologyTreatment

  • « Previous Page
  • 1
  • …
  • 181
  • 182
  • 183
  • 184
  • 185
  • …
  • 324
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences